Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2019’, provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)

- The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects

- The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

AbbVie Inc

Abivax SA

AlfaSigma SpA

Allergan Plc

Alpha Cancer Technologies Inc

Alvotech ehf

Amgen Inc

Anterogen Co Ltd

Antibe Therapeutics Inc ...

4D Pharma Plc

AbbVie Inc

Abivax SA

AlfaSigma SpA

Allergan Plc

Alpha Cancer Technologies Inc

Alvotech ehf

Amgen Inc

Anterogen Co Ltd

Antibe Therapeutics Inc

Aptevo Therapeutics Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Arven Ilac

Atlantic Bio Sci LLC

Atlantic Healthcare Plc

Avexegen Therapeutics Inc

Axim Biotechnologies Inc

BioLingus AG

Biond Biologics Ltd

BioXpress Therapeutics SA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Celltrion Inc

Celularity Inc

ChemoCentryx Inc

ChironWells GmbH

Chong Kun Dang Pharmaceutical Corp

Commence Bio Inc

Concenter BioPharma Silkim Ltd

Daiichi Sankyo Co Ltd

DBV Technologies SA

EA Pharma Co Ltd

Eisai Co Ltd

Eli Lilly and Co

Enterome Bioscience SA

Enzo Biochem Inc

ETX Pharma Inc

Evelo Biosciences Inc

Ferring International Center SA

FYB202 GmbH & Co KG

Galactica Biotech Ltd

Galapagos NV

Genentech Inc

GlaxoSmithKline Plc

Gossamer Bio Inc

IB Pharmaceuticals Inc

Inception Sciences Inc

InDex Pharmaceuticals Holding AB

Innovation Pharmaceuticals Inc

InSight Biopharmaceuticals Ltd

Inspyr Therapeutics Inc

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Jyant Technologies Inc

Kang Stem Biotech Co Ltd

Kashiv BioSciences LLC

Kyowa Hakko Kirin Co Ltd

Merck & Co Inc

Mesoblast Ltd

Metacrine Inc

Mitsubishi Tanabe Pharma Corp

Mycenax Biotech Inc

Naia Ltd

Nash Pharmaceuticals Inc

Nextbiotix SAS

Nichi-Iko Pharmaceutical Co Ltd

Nimbus Therapeutics LLC

Oncodesign SA

OSE Immunotherapeutics

Otsuka Holdings Co Ltd

Outlook Therapeutics Inc

PanTheryx Inc

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Protagonist Therapeutics Inc

Protheragen Inc

Provention Bio Inc

Qu Biologics Inc

Re-Pharm Ltd

RedHill Biopharma Ltd

Redx Pharma Plc

Saje Pharma LLC

Second Genome Inc

Seres Therapeutics Inc

Soligenix Inc

Synedgen Inc

Synlogic Inc

TaiwanJ Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Tetherex Pharmaceuticals Corp

The Cell-Factory BVBA

Theravance Biopharma Inc

Thetis Pharmaceuticals LLC

Tiziana Life Sciences Plc

Ventria Bioscience

VHsquared Ltd

Xbrane Biopharma AB

Table of Contents

Table of Contents

Introduction

Crohn's Disease (Regional Enteritis) – Overview

Crohn's Disease (Regional Enteritis) – Therapeutics Development

Crohn's Disease (Regional Enteritis) – Therapeutics Assessment

Crohn's Disease (Regional Enteritis ...

Table of Contents

Introduction

Crohn's Disease (Regional Enteritis) – Overview

Crohn's Disease (Regional Enteritis) – Therapeutics Development

Crohn's Disease (Regional Enteritis) – Therapeutics Assessment

Crohn's Disease (Regional Enteritis) – Companies Involved in Therapeutics Development

Crohn's Disease (Regional Enteritis) – Drug Profiles

Crohn's Disease (Regional Enteritis) – Dormant Projects

Crohn's Disease (Regional Enteritis) – Discontinued Products

Crohn's Disease (Regional Enteritis) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Tables

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by 4D Pharma Plc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by AbbVie Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Abivax SA, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by AlfaSigma SpA, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Allergan Plc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Alpha Cancer Technologies Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Alvotech ehf, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Amgen Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Anterogen Co Ltd, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Antibe Therapeutics Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Aptevo Therapeutics Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Arena Pharmaceuticals Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Artelo Biosciences Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Arven Ilac, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Atlantic Bio Sci LLC, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Atlantic Healthcare Plc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Avexegen Therapeutics Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Axim Biotechnologies Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by BioLingus AG, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Biond Biologics Ltd, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by BioXpress Therapeutics SA, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Boehringer Ingelheim GmbH, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Bristol-Myers Squibb Co, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Celgene Corp, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Celltrion Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Celularity Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by ChemoCentryx Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by ChironWells GmbH, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Commence Bio Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Concenter BioPharma Silkim Ltd, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by DBV Technologies SA, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by EA Pharma Co Ltd, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Eisai Co Ltd, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Eli Lilly and Co, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Enterome Bioscience SA, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Enzo Biochem Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by ETX Pharma Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Evelo Biosciences Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Ferring International Center SA, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by FYB202 GmbH & Co KG, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Galactica Biotech Ltd, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Galapagos NV, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Genentech Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by GlaxoSmithKline Plc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Gossamer Bio Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by IB Pharmaceuticals Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Inception Sciences Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by InDex Pharmaceuticals Holding AB, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by Innovation Pharmaceuticals Inc, H1 2019

Crohn's Disease (Regional Enteritis) – Pipeline by InSight Biopharmaceuticals Ltd, H1 2019

List of Figures

List of Figures

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Figures

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports